Circulating Tumor Cells (CTCs): A Potential Screening Test for Clinically Undetectable Breast Carcinoma

NCT ID: NCT01322750

Last Updated: 2011-03-25

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 3125 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2010-12-31
• Study Completion Date: 2023-01-31

Brief Summary

With an estimated > 2 million women with undetected breast cancer in the United States, the need for improved early detection is imperative. Early diagnosis for these women is key to minimizing quality life-years lost to disease and optimizing success of treatment. Evidence now exists supporting the finding that systemic spread is an early event in the natural history of breast cancer, manifested as a release of single cancer cells from the incident, clinically undetectable tumor, which circulate through the bloodstream and deposit within remote tissues. Reliable and accurate detection of these circulating tumor cells (CTCs) is now possible with a simple peripheral venous blood draw. This study hypothesizes that women with CTCs and no other signs of malignancy have clinically undetectable disease.

This study will attempt to validate this technology as a breast cancer screening test and acquire data to determine the clinical validity and utility of this proposed screening methodology on a relatively young, ethnically diverse population who are eligible military health care beneficiaries. Furthermore, this study will attempt to bank identified CTCs in order to perform additional molecular analyses in the future. The specific aims are to develop a simple, reliable, cost-effective, and clinically relevant breast cancer screening test in order to identify subclinical disease early in its natural history in subjects at risk of progression to clinically apparent disease over the ensuing decade. The ultimate goal is to decrease the treatment-related morbidity and cause-specific mortality of breast cancer. An experienced team devoted to the care of patients with breast disease has been assembled to achieve this goal.

Conditions

Breast Abnormality

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

With CTCs

Those individuals whom are identified with CTCs

No interventions assigned to this group

Without CTCs

Those individuals whom present and did not have CTCs

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Adults 18 years of age or older
• Mentally competent and willing to provide written informed consent prior to entering the study
• Military healthcare beneficiary
• Undergoing a diagnostic or therapeutic procedure (biopsy, lumpectomy, mastectomy) in the breast clinic or operating room.
• Present to the CBCP and willing to be followed at the CBCP during the course of treatment and follow-up

Exclusion Criteria

• Prior history of invasive carcinoma
• Presence of clinically-apparent metastatic disease
• Participants with known human immunodeficiency virus (HIV), any history of hepatitis, prion-mediated disease, drug resistant tuberculosis or other infectious disease presenting a significant risk to personnel handling tissue or blood-derived products shall be excluded from participation
• Participants with pre-existing coagulopathies or all other conditions, for whom invasive biopsy or surgery is medically contraindicated

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Bureau of Navy Medicine (BUMED)

UNKNOWN

Sponsor Role: collaborator

Walter Reed Army Medical Center

FED

Sponsor Role: lead

Responsible Party

Walter Reed Army Medical Center

Locations

Walter Reed Army Medical Center

Washington D.C., District of Columbia, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Thomas A Summers, MD

Role: CONTACT

thomas.summersjr@us.army.mil

202 782 7743

Facility Contacts

Thomas P Baker, MD

Role: primary

Thomas.P.Baker@us.army.mil

202-782-7743

Other Identifiers

354344

Identifier Type: -

Identifier Source: org_study_id